info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)

Increasing Prevalence of Completely New and Rare Diseases, Accelerating Orphan Drugs Market Growth

Pune, India, December, 2017/MRFR Press Release/- Market Research Future published a Half-Cooked research report on “Global Orphan Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.

Orphan Drugs market-Overview

Orphan drugs are used to treat rare disease and therefore, there is an increasing demand for diagnosis and treatment services for rare diseases. Increasing demand for orphan drugs for rare disease such as Aarskog Syndrome, Abetalipoproteinemia, Yellow Fever, Yellow Nail syndrome, Von Hippel-Lindau Disease, Von Willebrand Disease, Waardenburg Syndrome, diabetic macular edema, Autism spectrum disorder (ASD), Asperger syndrome, and others and rising research and development expenses by the developing countries drive the growth of the orphan drugs market. Furthermore, government R&D Grants, FDA fee waivers, favorable reimbursement policy, and premium pricing due to low competition also influence the growth of the market. Unmet medical needs such as drugs for rare diseases is also another important driver of the orphan drug market. According to FDA, only 5% of rare diseases have approved drug treatment with only 326 new drugs being approved by the FDA and brought to market.

Increasing rate of screening of patients with rare diseases has led to an increase in the awareness of treatment methods for rare diseases. Prolonged exclusivity of patent and data and support from organizations promoting research in this field.

Key players in the Orphan Drugs market:

  • Hoffmann-La Roche AG (Germany), Celgene Corporation (U.S.), Alexion Pharmaceuticals, Inc. (U.S.), Novartis AG (Germany), Takeda Pharmaceuticals Company Limited (Japan), Biogen Idec Limited (U.K), Eli Lilly (U.S.), Bristol-Myers Squibb (U.K), Vertex pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Sanofi (France), and Johnson & Johnson (U.S.).
  • Key developments:

    Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap.

    Browse Full Report @ https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312

    Johnson & Johnson:

    Headquartered at New Brunswick, New Jersey, Johnson & Johnson Services Inc. is an American medical devices, pharmaceutical and consumer goods manufacturing company. Consumer care of Johnson & Johnson Services Inc. includes OTC, Beauty, Baby Care, Oral Care, Women’s Health, Wound Care and other products.

    Novartis AG:

    Novartis AG operates through three operating divisions, namely; Pharmaceuticals, Alcon (eye care) and Sandoz (generics).

    GlaxoSmithKline:

    November 2016: GlaxoSmithKline and Innoviva, Inc. announced a new drug application for FF/UMEC/VI in the US of once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patient’s chronic obstructive pulmonary disease (COPD).

    December 2015: GlaxoSmithKline announced that it has been granted selling authorisation for Nucala (mepolizumab) by the European Commission. Nucala (mepolizumab) is used as an add-on treatment for refractory eosinophilic asthma in adult patients. The drug is approved for use in 31 countries in Europe covered by the European Medicines Agency (EMA).

    October, 2015: GlaxoSmithKline completed the acquisition of Novartis Healthcare's vaccines business. It will enhance the company’s growth in vaccine portfolio.

    October, 2015: GlaxoSmithKline sold its oncology portfolio to Novartis India. By selling oncology division, the company will be more focused on other segments such as vaccine business. F . Hoffmann-La Roche AG:

    Headquartered in Basel, Switzerland; F. Hoffmann-La Roche AG is a company manufacturing and marketing number of innovative diagnostic tests and medicines, across the globe. The company offers various products in the pharmaceutical, diagnostics and research industry.

    June, 2017: F. Hoffmann-La Roche AG acquired mySugr to form a leading platform for digital diabetes management.

    August, 2015: F. Hoffmann-La Roche AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche paid GeneWEAVE shareholders USD 190 million upfront and up to USD 235 million in contingent product related milestones.

    February 2015   : F. Hoffmann-La Roche AG announced the collaboration with BioMed X for the development of Nanomaterial-Based Biosensors for Near-Patient Testing.

    September 2014: F. Hoffmann-La Roche AG launched Elecsys anti-Müllerian Hormone (AMH) fertility test for assessment of ovarian reserve for pregnancy.

    Sanofi:

    Sanofi is a UK based global life sciences company which was incorporated in the year 2004.

    January, 2014: Sanofi & Transgene SA have launched a construction phase of the manufacturing platform dedicated to the production of viral vectors. This launch will help- Sanofi to enable to produce a new breakthrough class of APIs.

    January, 2014: Sanofi and Isarna Therapeutics GmbH signed a strategic manufacturing agreement under which Sanofi will manufacture clinical- and commercial-grade antisense oligonucleotide (ASO) compounds for Isarna that will enable Isarna to advance its promising next generation ASOs rapidly into clinical trials. This will help to establish key relationships with leaders in the industry.

    Leading companies partner with us for data-driven Insights
    client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
    Kindly complete the form below to receive a free sample of this Report
    Please fill in Business Email for Quick Response

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Report details
    Base Year 2017
    Companies Covered 15
    Pages 159
    Certified Global Research Member
    Isomar fd.webp Wcrc 57.webp
    Why Choose Market Research Future?
    • Vigorous research methodologies for specific market.
    • Knowledge partners across the globe
    • Large network of partner consultants.
    • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
    • Trusted by fortune 500 companies/startups/ universities/organizations
    • Large database of 5000+ markets reports.
    • Effective and prompt pre- and post-sales support.
    Tailored for You
    • Dedicated Research on any specifics segment or region.
    • Focused Research on specific players in the market.
    • Custom Report based only on your requirements.
    • Flexibility to add or subtract any chapter in the study.
    • Historic data from 2014 and forecasts outlook till 2040.
    • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
    • Provide cross segmentation in applicable scenario/markets.